Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
  • A61K31/5375—1,4-Oxazines, e.g. morpholine
  • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
  • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
  • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
  • A61K47/38—Cellulose; Derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
  • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
  • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
  • A61K9/1605—Excipients; Inactive ingredients
  • A61K9/1617—Organic compounds, e.g. phospholipids, fats
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
  • A61K9/1605—Excipients; Inactive ingredients
  • A61K9/1629—Organic macromolecular compounds
  • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/4841—Filling excipients; Inactive ingredients
  • A61K9/4866—Organic macromolecular compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
  • A61P35/02—Antineoplastic agents specific for leukemia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
  • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
  • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
  • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

• the present invention relates to solid dispersions comprising an apoptosis-inducing agent, to pharmaceutical dosage forms comprising such dispersions, to processes for preparing such dispersions and dosage forms and to methods of use thereof for treating diseases characterized by overexpression of anti-apoptotic Bcl-2 family proteins.
• Bcl-2 proteins correlates with resistance to chemotherapy, clinical outcome, disease progression, overall prognosis or a combination thereof in various cancers and disorders of the immune system.
• NHL non-Hodgkin's lymphoma
• Treatment of follicular lymphoma typically consists of biologically-based or combination chemotherapy.
• Combination therapy with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) is routinely used, as is combination therapy with rituximab, cyclophosphamide, vincristine and prednisone (RCVP).
• R-CHOP combination therapy with rituximab, cyclophosphamide, vincristine and prednisone
• RCVP prednisone
• Single-agent therapy with rituximab targeting CD20, a phosphoprotein uniformly expressed on the surface of B-cells
• fludarabine is also used. Addition of rituximab to chemotherapy regimens can provide improved response rate and increased progression-free survival.
• Radioimmunotherapy agents can be used to treat refractory or relapsed NHL.
• First-line treatment of patients with aggressive large B-cell lymphoma typically consists of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP), or dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin and rituximab (DA-EPOCH-R).
• lymphomas respond initially to any one of these therapies, but tumors typically recur and eventually become refractory. As the number of regimens patients receive increases, the more chemotherapy-resistant the disease becomes. Average response to first-line therapy is approximately 75%, 60% to second-line, 50% to third-line, and about 35-40% to fourth-line therapy. Response rates approaching 20% with a single agent in a multiple relapsed setting are considered positive and warrant further study.
• neoplastic diseases for which improved therapies are needed include leukemias such as chronic lymphocytic leukemia (like NHL, a B-cell lymphoma) and acute lymphocyctic leukemia.
• leukemias such as chronic lymphocytic leukemia (like NHL, a B-cell lymphoma) and acute lymphocyctic leukemia.
• CLL Chronic lymphoid leukemia
• CLL is the most common type of leukemia.
• CLL is primarily a disease of adults, more than 75% of people newly diagnosed being over the age of 50, but in rare cases it is also found in children.
• Combination chemotherapies are the prevalent treatment, for example fludarabine with cyclophosphamide and/or rituximab, or more complex combinations such as CHOP or R-CHOP.
• Acute lymphocyctic leukemia also known as acute lymphoblastic leukemia (ALL)
• ALL acute lymphoblastic leukemia
• New therapies are still needed to provide further improvement in survival rates.
• Bcl-2 and Bcl-X L have been shown to confer chemotherapy resistance in short-term survival assays in vitro and, more recently, in vivo. This suggests that if improved therapies aimed at suppressing the function of Bcl-2 and Bcl-X L can be developed, such chemotherapy-resistance could be successfully overcome.
• Bcl-2 proteins in bladder cancer brain cancer, breast cancer, bone marrow cancer, cervical cancer, CLL, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, prostate cancer, small cell lung cancer, spleen cancer and the like is described in International Patent Publication Nos. WO 2005/024636 and WO 2005/049593.
• Bcl-2 proteins Compounds that occupy a binding site on Bcl-2 proteins are known.
• such compounds desirably have high binding affinity, exhibiting for example K i ⁇ 1 nM, preferably ⁇ 0.1 nM, more preferably ⁇ 0.01 nM, to proteins of the Bcl-2 family, specifically Bcl-2, Bcl-X L and Bcl-w. It is further desirable that they be formulated in a manner that provides high systemic exposure after oral administration.
• a typical measure of systemic exposure after oral administration of a compound is the area under the curve (AUC) resulting from graphing plasma concentration of the compound versus time from oral administration.
• Liquid dosage forms can be useful for some drugs of low aqueous solubility, provided a suitable pharmaceutically acceptable solvent system (generally lipid-based) can be found that provides adequate drug loading without posing solubility or storage-stability issues.
• a suitable pharmaceutically acceptable solvent system generally lipid-based
• Other approaches that have been proposed for such drugs include solid dispersions, which bring their own challenges.
• a solid dosage form is often preferred over a liquid dosage form.
• oral solid dosage forms of a drug provide lower bioavailability than oral solutions of the drug.
• a solvent evaporation method for preparing solid dispersions is described therein, mentioning as an example a solid dispersion of etoricoxib, prepared by a process that includes dissolving polyethylene glycol (PEG), polyvinylpyrrolidone (PVP or povidone) and the active ingredient in 2-propanol.
• PEG polyethylene glycol
• PVP polyvinylpyrrolidone
• Apoptosis-inducing drugs that target Bcl-2 family proteins such as Bcl-2 and Bcl-X L are best administered according to a regimen that provides continual, for example daily, replenishment of the plasma concentration, to maintain the concentration in a therapeutically effective range.
• This can be achieved by daily parenteral, e.g., intravenous (i.v.) or intraperitoneal (i.p.) administration.
• daily parenteral administration is often not practical in a clinical setting, particularly for outpatients.
• a solid dosage form with acceptable oral bioavailability would be highly desirable.
• Such a dosage form, and a regimen for oral administration thereof would represent an important advance in treatment of many types of cancer, including NHL, CLL and ALL, and would more readily enable combination therapies with other chemotherapeutics.
• a solid orally deliverable dosage form comprising such a solid dispersion, optionally together with one or more additional excipients.
• the compound present in the finished solid dispersion can be in the same chemical form (e.g., parent compound or salt) as in the API used to prepare it.
• the process can comprise one or more additional steps wherein the API is converted from parent compound to salt or vice versa.
• the process further comprises, prior to removing the solvent, adding a base for conversion of the API in salt form to its corresponding parent compound, and optionally extracting a by-product of such conversion (e.g., a salt by-product) from the resulting mixture.
• the process further comprises, prior to removing the solvent, adding an acid for conversion of the API in parent compound form to a salt, for example an acid addition salt.
• neoplastic diseases include cancers.
• a specific illustrative type of cancer that can be treated according to the present method is non-Hodgkin's lymphoma (NHL).
• Another specific illustrative type of cancer that can be treated according to the present method is chronic lymphocytic leukemia (CLL).
• CLL chronic lymphocytic leukemia
• ALL acute lymphocytic leukemia
• a solid dispersion in accordance with the present disclosure comprises an active ingredient in an essentially non-crystalline or amorphous form, which is usually more soluble than the crystalline form.
• the term “solid dispersion” herein encompasses systems having small solid-state particles (e.g., essentially non-crystalline or amorphous particles) of one phase dispersed in another solid-state phase. More particularly, the present solid dispersions comprise particles of one or more active ingredients dispersed in an inert carrier or matrix in solid state, and can be prepared by melting or solvent methods or by a combination of melting and solvent methods. According to the present invention a solvent method as described herein is particularly favored.
• An “amorphous form” refers to a particle without definite structure, i.e., lacking crystalline structure.
• essentially non-crystalline herein means that no more than about 5%, for example no more than about 2% or no more than about 1% crystallinity is observed by X-ray diffraction analysis. In a particular embodiment, no detectable crystallinity is observed by one or both of X-ray diffraction analysis or polarization microscopy. In this regard it is to be noted that, when no detectable crsytallinity is observed, the solid dispersion referenced herein may additionally or alternatively be described as a solid solution.
• Compounds of Formula I, including salts thereof, useful herein typically have very low solubility in water, being classed as essentially insoluble, i.e., having a solubility of less than about 10 ⁇ g/ml.
• active ingredients are, for example, Biopharmaceutics Classification System (BCS) Class IV drug substances that are characterized by low solubility and low permeability (see “Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system”, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), August 2000).
• aqueous solubility of many compounds is pH-dependent; in the case of such compounds the solubility of interest herein is at a physiologically relevant pH, for example a pH of about 1 to about 8.
• the drug has a solubility in water, at least at one point in a pH range from about 1 to about 8, of less than about 10 ⁇ g/ml, in some cases less than about 1 ⁇ g/ml or even less than about 0.1 ⁇ g/ml.
• a particular compound useful herein has a solubility in water at pH 4 of ⁇ 0.004 ⁇ g/ml.
• Solid dispersions of the present invention comprise as active ingredient a compound of Formula I as defined above, or a pharmaceutically acceptable salt of such a compound.
• they may further comprise a second active ingredient, for example a therapeutic agent useful in combination therapy with the compound of Formula I as indicated hereinbelow.
• the compound has Formula I where R 0 is chloro.
• the compound has Formula I where R 1 is methyl or methoxy, R 2 is methyl, and R 3 and R 4 are each H.
• the compound has Formula I where R 5 is trifluoromethyl, trifluoromethylsulfonyl, chloro, bromo or nitro.
• R 5 is trifluoromethyl, trifluoromethylsulfonyl, chloro, bromo or nitro.
• the compound has Formula I where (a) R 0 is chloro, (b) R 1 is methyl or methoxy, R 2 is methyl, and R 3 and R 4 are each H, and (c) R 5 is trifluoromethyl, trifluoromethylsulfonyl, chloro, bromo or nitro.
• R 6 is a 3- to 7-membered carbocyclic or heterocyclic ring, optionally substituted as defined above.
• R 6 is a saturated carbocyclic (i.e., cycloalkyl) ring, for example but not limited to cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, in each case optionally substituted as more fully described below.
• heterocyclic herein embraces saturated and partly and fully unsaturated ring structures having 4 to 7 ring atoms, one or more of which are heteroatoms independently selected from N, O and S. Typically the heterocyclic ring has no more than two such heteroatoms.
• R 6 is a saturated heterocyclic ring, for example but not limited to azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, imazolidinyl, pyrazolidinyl, tetrahydrofuranyl, oxazolidinyl, isoxazolidinyl, thiophanyl, thiazolidinyl, isothiazolidinyl, piperidinyl, piperazinyl, tetrahydropyranyl, 1,4-dioxanyl, morpholinyl or tetrahydrothiopyranyl, in each case optionally substituted as more fully described below.
• R 6 is a carbocyclic or heterocyclic ring, for example a saturated ring as described immediately above, it can be unsubstituted or substituted at up to three positions on the ring.
• Substituents if present, comprise no more than two Z 1 groups and/or no more than one Z 2 group.
• Z 1 groups are independently selected from (a) C 1-4 alkyl, C 2-4 alkenyl, C 1-4 alkoxy, C 1-4 alkylthio, C 1-4 alkylamino, C 1-4 alkylsulfonyl, C 1-4 alkylsulfonylamino, C 1-4 alkylcarbonyl, C 1-4 alkylcarbonylamino and C 1-4 alkylcarboxy, each optionally substituted with one or more substituents independently selected from halo, hydroxy, C 1-4 alkoxy, amino, C 1-4 alkylamino, di-(C 1-4 alkyl)amino and cyano, (b) halo, (e) hydroxy, (f) amino and (g) oxo groups.
• Illustrative examples of such Z 1 groups include without limitation methyl, cyanomethyl, methoxy, fluoro, hydroxy, amino and methylsulfonyl.
• the Z 2 group if present, is a further 3- to 7-membered carbocyclic or heterocyclic ring, optionally substituted with no more than two Z 1 groups as described above.
• Ring Z 2 if present, is typically but not necessarily saturated, and in most cases is not further substituted.
• Z 2 is a saturated carbocyclic ring, for example but not limited to cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
• Z 2 is a saturated heterocyclic ring, for example but not limited to azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, imazolidinyl, pyrazolidinyl, tetrahydrofuranyl, oxazolidinyl, isoxazolidinyl, thiophanyl, thiazolidinyl, isothiazolidinyl, piperidinyl, piperazinyl, tetrahydropyranyl, 1,4-dioxanyl, morpholinyl or tetrahydrothiopyranyl.
• R 6 is a group NR 7 R 8 , where R 7 and R 8 are each independently H or R 9 —(CH 2 ) m — groups, no more than one of R 7 and R 8 being H, where each R 9 is independently a 3- to 7-membered carbocyclic or heterocyclic ring, optionally substituted with no more than two Z 1 groups as defined above, and each m is independently 0 or 1.
• Each of rings R 9 is typically but not necessarily saturated, and in most cases is unsubstituted.
• Illustrative carbocyclic rings at R 7 and/or R 8 include without limitation cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
• Illustrative heterocyclic rings at R 7 and/or R 8 include without limitation azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, imazolidinyl, pyrazolidinyl, tetrahydrofuranyl, oxazolidinyl, isoxazolidinyl, thiophanyl, thiazolidinyl, isothiazolidinyl, piperidinyl, piperazinyl, tetrahydropyranyl, 1,4-dioxanyl, morpholinyl or tetrahydrothiopyranyl.
• R 6 is selected from the group consisting of 4-methoxycyclohexyl, cis-4-hydroxy-4-methylcyclohexyl, trans-4-hydroxy-4-methylcyclohexyl, 4-morpholin-4-ylcyclohexyl, (3R)-1-(methylsulfonyl)pyrrolidin-3-yl, (3R)-1-tetrahydro-2H-pyran-4-ylpyrrolidin-3-yl, tetrahydro-2H-pyran-4-yl, (3S)-tetrahydro-2H-pyran-3-yl, 4-methoxytetrahydro-2H-pyran-4-yl, 4-fluorotetrahydro-2H-pyran-4-yl, 4-aminotetrahydro-2H-pyran-4-yl, 1-(cyanomethyl)piperidin-4-yl, 4-fluoro-1-oxetan-3-ylpiperidin-4-yl, 1-tetrahydro-2H-pyr
• Compounds of Formula I may contain asymmetrically substituted carbon atoms in the R- or S-configuration; such compounds can be present as racemates or in an excess of one configuration over the other, for example in an enantiomeric ratio of at least about 85:15.
• the compound can be substantially enantiomerically pure, for example having an enantiomeric ratio of at least about 95:5, or in some cases at least about 98:2 or at least about 99:1.
• Compounds of Formula I may alternatively or additionally contain carbon-carbon double bonds or carbon-nitrogen double bonds in the Z- or E-configuration, the term “Z” denoting a configuration wherein the larger substituents are on the same side of such a double bond and the term “E” denoting a configuration wherein the larger substituents are on opposite sides of the double bond.
• the compound can alternatively be present as a mixture of Z- and E-isomers.
• Compounds of Formula I may alternatively or additionally exist as tautomers or equilibrium mixtures thereof wherein a proton shifts from one atom to another.
• tautomers illustratively include keto-enol, phenol-keto, oxime-nitroso, nitro-aci, imine-enamine and the like.
• the API present in the solid dispersion is selected from compounds specifically identified in above-referenced U.S. application Ser. No. 12/787,682 (U.S. 2010/0305122) in Examples 1-378 thereof, and pharmaceutically acceptable salts of such compounds, independently of whether these compounds are individually embraced by the present Formula I. Compounds 1-378 of these Examples, and illustrative procedures for their synthesis, are reproduced hereinbelow.
• the API present in the solid dispersion is selected from Compounds 1-378 and pharmaceutically acceptable salts thereof, but only to the extent that such Examples are individually embraced by the present Formula I.
• the entire disclosure of U.S. application Ser. No. 12/787,682 (U.S. 2010/0305122) is expressly incorporated herein by reference.
• This Compound was prepared by substituting 3-(N-morpholinyl)-propylamine for 1-(tetrahydropyran-4-yl)methylamine in the procedure for Compound 1F.
• This Compound was prepared by substituting 4-amino-N-methylpiperidine for 1-(tetrahydropyran-4-yl)methylamine in the procedure for Compound 1F.
• This Compound was prepared by substituting ethyl 2,4-difluorobenzoate for methyl 2,4-difluorobenzoate and 4-hydroxycarbazole for Compound 3G in the procedure for Compound 3H.
• This Compound was prepared by substituting Compound 7A for Compound 3H in the procedure for Compound 3I.
• This Compound was prepared by substituting Compound 7B for Compound 3I in the procedure for Compound 3J, except here upon completion of the reaction, water and 2N HCl were added to adjust the pH to 2, and the HCl salt of the product was extracted using CHCl 3 /CH 3 OH.
• This Compound was prepared by substituting Compound 7C for Compound 1E and Compound 4A for Compound 1F in the procedure for Compound 1G, except here the purification was done by preparative HPLC using a C18 column, 250 ⁇ 50 mm, 10 ⁇ , and eluting with a gradient of 20-100% CH 3 CN vs. 0.1% trifluoroacetic acid in water, giving the product as a bistrifluoroacetate salt.
• This Compound was prepared by substituting 3-(pyrrolidin-1-yl)propan-1-amine for 1-(tetrahydropyran-4-yl)methylamine in the procedure for Compound 1F.
• This Compound was prepared by substituting Compound 7C for Compound 1E and Compound 8A for Compound 1F in the procedure for Compound 1G, except here the purification was done by preparative HPLC using a C18 column, 250 ⁇ 50 mm, 10 ⁇ , and eluting with a gradient of 20-100% CH 3 CN vs. 0.1% trifluoroacetic acid in water, giving the product as a bistrifluoroacetate salt.
• trans-4-morpholinocyclohexanamine dihydrochloride (5 g, 19.44 mmol), 4-fluoro-3-nitrobenzenesulfonamide (4.32 g, 19.63 mmol) and triethylamine (20 ml, 143 mmol) in tetrahydrofuran (60 ml) was stirred for 16 hours at room temperature.
• the solid product was filtered off, washed with tetrahydrofuran, ether, dichloromethane (3 ⁇ ) and dried under vacuum.
• This compound was prepared by substituting 2-methoxyethylamine for 1-(tetrahydropyran-4-yl)methylamine in the procedure for Compound 1F.
• This racemic mixture was prepared by substituting (tetrahydro-2H-pyran-3-yl)methanamine for 1-(tetrahydropyran-4-yl)methylamine in the procedure for Compound 1F.
• the racemic mixture of Compound 11A was resolved by chiral SFC on an AD column (21 mm i.d.x 250 mm in length) using a gradient of 10-30% 0.1% diethylamine methanol in CO 2 over 15 minutes (oven temperature: 40° C.; flow rate: 40 ml/minute) to provide the title compound.
• the racemic mixture of Compound 11A was resolved by chiral SFC on an AD column (21 mm i.d.x 250 mm in length) using a gradient of 10-30% 0.1% diethylamine methanol in CO 2 over 15 minutes (oven temperature: 40° C.; flow rate: 40 ml/minute) to provide the title compound.
• This Compound was prepared by substituting 1-(tetrahydropyran-4-yl)methylamine for 2-methoxyethanamine in the procedure for Compound 16A.
• the title compound was prepared by substituting 5,6-dichloropyridine-3-sulfonyl chloride for 5-bromo-6-chloropyridine-3-sulfonyl chloride in the procedure for Compound 36A.
• aqueous layer was adjusted to pH ⁇ 4 with 1N aqueous HCl and the organic layer was separated, washed with brine (50 ml), dried over magnesium sulfate, filtered, and concentrated.
• the residue was loaded onto silica gel (GraceResolv 40 g) and eluted using a gradient of 0.5% to 7.5% methanol/dichloromethane over 30 minutes. This solid was treated with HCl (4.0M in dioxane, 5 ml) at room temperature for 1 hour and concentrated to give the title compound.
• the title compound was prepared by substituting Compound 66A for Compound 1F and Compound 3J for Compound 1E in the procedure for Compound 1F, with the exception that the product was purified on a silica gel column eluted with 4% methanol in dichloromethane.
• the title compound was prepared by substituting 4,4-dimethyl-2-methoxycarbonylcyclohexanone for 5,5-dimethyl-2-methoxycarbonylcyclohexanone in the procedure for Compound 3A.
• the title compound was prepared by replacing 4′-chlorobiphenyl-2-carboxaldehyde with Compound 75D and tert-butyl piperazine-1-carboxylate with Compound 15F in the procedure for Compound 1A.
• N-Benzyl-1,1-dioxotetrahydro-2H-thiopyran-4-amine (2.00 g) was added to ethanol (40 ml) in a pressure bottle.
• Palladium hydroxide on carbon (0.587 g,) was added and the solution was stirred under 30 psi of hydrogen at room temperature for 2 hours.
• the mixture was filtered though a nylon membrane and the solvent was removed under vacuum.
• the obtained material was chromatographed on silica gel a second time with 10-40% ethyl acetate in CH 2 Cl 2 as the eluent, triturated with diethyl ether and dried under vacuum at 45° C. to give the product.
• the title compound was prepared by substituting Compound 87C for Compound 1E in the procedure for Compound 1G, except here the crude was purified by preparative HPLC using a 250 ⁇ 50 mm C18 column and eluting with 20-100% CH 3 CN vs. 0.1% trifluoroacetic acid in water, giving the product as a trifluoroacetate salt.
• the title compound was prepared by substituting Compound 87C for Compound 1E and Compound 2A for Compound 1F in the procedure for Compound 1G, except here the crude was purified by preparative HPLC using a 250 ⁇ 50 mm C18 column and eluting with 20-100% CH 3 CN vs. 0.1% trifluoroacetic acid in water, giving the product as a trifluoroacetate salt.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Epidemiology (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Immunology (AREA)
• Molecular Biology (AREA)
• Biophysics (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Hematology (AREA)
• Oncology (AREA)
• Transplantation (AREA)
• Inorganic Chemistry (AREA)
• Biochemistry (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Nutrition Science (AREA)
• Physiology (AREA)

Priority Applications (5)

Applications Claiming Priority (2)

Related Child Applications (1)

Publications (1)

Family

ID=44947217

Family Applications (5)

Family Applications After (4)

Country Status (16)

Cited By (35)

Families Citing this family (41)

Family Cites Families (87)

• 2011
  • 2011-10-27 CA CA3152557A patent/CA3152557A1/en active Pending
  • 2011-10-27 SG SG10201801794WA patent/SG10201801794WA/en unknown
  • 2011-10-27 KR KR1020137013699A patent/KR102095698B1/ko active Active
  • 2011-10-27 IL IL225340A patent/IL225340A/en active IP Right Grant
  • 2011-10-27 CA CA2811805A patent/CA2811805A1/en not_active Abandoned
  • 2011-10-27 EP EP11782300.5A patent/EP2632436B1/en active Active
  • 2011-10-27 JP JP2013536811A patent/JP6068352B2/ja active Active
  • 2011-10-27 BR BR112013009093-6A patent/BR112013009093B1/pt active IP Right Grant
  • 2011-10-27 RU RU2013124824/15A patent/RU2598345C2/ru active
  • 2011-10-27 WO PCT/US2011/058024 patent/WO2012058392A1/en not_active Ceased
  • 2011-10-27 SG SG2013029772A patent/SG189471A1/en unknown
  • 2011-10-27 MX MX2013004778A patent/MX349533B/es active IP Right Grant
  • 2011-10-27 AU AU2011319842A patent/AU2011319842B2/en active Active
  • 2011-10-27 CN CN201180052601.1A patent/CN103167867B/zh active Active
  • 2011-10-27 NZ NZ608274A patent/NZ608274A/en unknown
  • 2011-10-27 ES ES11782300T patent/ES2699205T3/es active Active
  • 2011-10-27 KR KR1020187014015A patent/KR20180059560A/ko active Pending
  • 2011-10-27 US US13/282,773 patent/US20120277210A1/en not_active Abandoned
  • 2011-10-28 TW TW100139446A patent/TWI598333B/zh active
• 2014
  • 2014-11-10 US US14/537,392 patent/US10213433B2/en active Active
• 2019
  • 2019-01-03 US US16/239,199 patent/US20190275051A1/en not_active Abandoned
• 2021
  • 2021-06-07 US US17/341,158 patent/US20220125796A1/en not_active Abandoned
• 2024
  • 2024-08-20 US US18/809,439 patent/US20250161318A1/en active Pending

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events